Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · lung-landscapes@6

C3N-02494

— · cohortSQ2

bdbf23b7-fded-5cfd-973e-c0df0e736ff6

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
cohortSQ2
subtype
cohortSQ2
age_years
66.98699521

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • MYC_TARGETS_V2+0.640
  • MYC_TARGETS_V1+0.540
  • E2F_TARGETS+0.510
  • G2M_CHECKPOINT+0.410
  • ALLOGRAFT_REJECTION+0.280
  • MTORC1_SIGNALING+0.190
  • DNA_REPAIR+0.180
  • OXIDATIVE_PHOSPHORYLATION+0.180
  • UNFOLDED_PROTEIN_RESPONSE+0.180
  • REACTIVE_OXYGEN_SPECIES_PATHWAY+0.160

Top 10 suppressed

  • INTERFERON_ALPHA_RESPONSE-0.430
  • TGF_BETA_SIGNALING-0.350
  • ANGIOGENESIS-0.320
  • HYPOXIA-0.320
  • COAGULATION-0.310
  • EPITHELIAL_MESENCHYMAL_TRANSITION-0.310
  • ESTROGEN_RESPONSE_EARLY-0.280
  • MYOGENESIS-0.270
  • COMPLEMENT-0.260
  • PROTEIN_SECRETION-0.260

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

9 twins match this tumor's tissue · 1 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1TCGA-22-4613-01A-01R-1443-07
lung-landscapes@6
—cohortSQ20.875
220030039.TNBC
breast-umap@18
—E0.855
3SRR8518298
breast-umap@18
—E0.854
4SRR1313148
breast-umap@18
—E0.851
5NB4_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE
ccle-aml@v2024.1
AML—0.847
6TCGA-O2-A52S-01A-11R-A262-07
lung-landscapes@6
—cohortSQ20.844
720090275.TNBC
breast-umap@18
—E0.843
8TCGA-AN-A04C-01A-21R-A034-07
breast-umap@18
—C0.843
9SRR15030859
colon-landscapes@1
——0.842
10TCGA-22-5481-01A-31R-1949-07
lung-landscapes@6
—cohortMD10.838

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 18 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
MYC_TARGETS_V20.640Idelalisib— uncovered
MYC_TARGETS_V10.540Inavolisib— uncovered
E2F_TARGETS0.510Inavolisib— uncovered
G2M_CHECKPOINT0.410Inavolisib— uncovered
ALLOGRAFT_REJECTION0.280Idelalisib— uncovered
MTORC1_SIGNALING0.190Inavolisib— uncovered
DNA_REPAIR0.180Idelalisib— uncovered
OXIDATIVE_PHOSPHORYLATION0.180Remibrutinib— uncovered
UNFOLDED_PROTEIN_RESPONSE0.180Idelalisib— uncovered
REACTIVE_OXYGEN_SPECIES_PATHWAY0.160Inavolisib— uncovered
WNT_BETA_CATENIN_SIGNALING0.130Inavolisib— uncovered
PI3K_AKT_MTOR_SIGNALING0.110Inavolisib— uncovered
SPERMATOGENESIS0.090Inavolisib— uncovered
IL2_STAT5_SIGNALING0.050Idelalisib— uncovered
MITOTIC_SPINDLE0.050Inavolisib— uncovered
XENOBIOTIC_METABOLISM0.040Inavolisib— uncovered
FATTY_ACID_METABOLISM0.010Inavolisib— uncovered
KRAS_SIGNALING_DN0.010Remibrutinib— uncovered